Steinhausen, 06. January 2020, Selecta is pleased to announce the appointment of Ms. Dorothée Deuring to the Board as a Non-Executive Director with immediate effect.

Ms. Dorothée Deuring

Dorothée Deuring is a corporate finance specialist, with extensive experience and expertise in Corporate Finance and Investment Banking. She has held leading roles in Investments, Mergers & Acquisitions and Corporate Finance and Advisory services for F. Hoffmann La Roche, Bankhaus SAL. Oppenheim JR & CIE, and UBS AG.

Ms. Deuring is a graduate of Biochemistry with a Master of Science degree from Université Louis Pasteur, Strasbourg. Many of her early roles enabled her to develop a deep knowledge of the food ingredients, life sciences and chemical industries. In addition to her direct industrial experience, she worked as a consultant at McKinsey & Company and holds an MBA degree from INSEAD.

Since 2014, Ms. Deuring has been actively engaged in several high profile Non-Executive Director roles. She serves on the Board and Audit Committee of publicly listed Bilfinger SE (Germany, engineering), and Elementis plc (UK, specialty chemicals), as well as stateowned Axpo Holding AG (Switzerland, power generation). She recently joined the VCbacked biotech, Piqur Therapeutics AG (Switzerland).

Chairman, David Hamill said: “We are delighted to welcome Ms. Deuring to the Board of Selecta. She brings significant and highly relevant expertise to the Board. Dorothée’s extensive experience in Industry and Commercial operations as well as her Consulting and Corporate Financial Advisory work will enable her to contribute strongly as we develop and execute our plans to the further grow and develop the Selecta business.”